Neogen (Neogen) Total Current Assets : $602.5 Mil (As of Feb. 2024)

View and export this data going back to 1989. Start your Free Trial

What is Neogen Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Neogen's total current assets for the quarter that ended in Feb. 2024 was $602.5 Mil.

Neogen Total Current Assets Historical Data

The historical data trend for Neogen's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen Total Current Assets Chart

Neogen Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Total Current Assets

Get a 7-Day Free Trial

449.53

537.41

591.45

626.80

585.93

Neogen Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Current Assets	Get a 7-Day Free Trial															555.37	585.93	583.79	624.37	602.47

Neogen Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Neogen's Total Current Assets for the fiscal year that ended in May. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	245.569	+	153.253	+	133.812	+	53.297
	=	585.9

Neogen's Total Current Assets for the quarter that ended in Feb. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	168.447	+	173.592	+	182.39	+	78.042
	=	602.5

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Neogen (NAS:NEOG) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Neogen's Liquidation Value for the quarter that ended in Feb. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	168.447	-	1436.318	+	0.75 * 173.592	+	0.5 * 182.39
=	-1,046.5

Neogen Total Current Assets Related Terms

Thank you for viewing the detailed overview of Neogen's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Neogen (Neogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » Total Current Assets

Comparable Companies

SHC RDNT GH NEO TWST MYGN VCYT OPK LAB FLGT TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

NG2:Germany NG2:Germany

Address

620 Lesher Place, Lansing, MI, USA, 48912

Website

https://www.neogen.com

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.

Executives

William T Boehm	director
Douglas Edward Jones	officer: Vice President, CCO	620 LESHER PLACE, LANSING MI 48912
Jason Warren Lilly	officer: Vice President	620 LESHER PLACE, LANSING MI 48912
James P Tobin	director	620 LESHER PLACE, LANSING MI 48895
David H. Naemura	officer: VP & CFO	C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Amy M Rocklin	officer: Chief Legal & Reg. Officer	620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan	officer: VP & CFO	620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta	director	C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
John Edward Adent	officer: Chief Executive Officer	822 7TH STREET, SUITE 740, GREELEY CO 80631
Darci L Vetter	director	620 LESHER PLACE, LANSING MI 48912
Ronald D Green	director	620 LESHER PLACE, LANSING MI 48912
James C Borel	director	1007 MARKET STREET, WILMINGTON DE 19898
Terri A Morrical	officer: General Manager
G Bruce Papesh	director	726 APPLEGATE LANE, EAST LANSING MI 48823